Rafina Innovations Inc. (VICA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rafina Innovations Inc. (VICA) trades at $0.001. Rafina Innovations Inc. is a UK-based medical technology company focused on developing, researching, commercializing, and marketing medical devices. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for VICA: VICA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VICA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on VICA.
How is this calculated? →Rafina Innovations Inc. (VICA) Healthcare & Pipeline Overview
Rafina Innovations Inc. is a UK-based medical technology firm specializing in the development, research, commercialization, and marketing of medical devices and innovative methods. It also manages rehabilitation clinics for prosthetics, orthotics, and diabetic foot care across Southern Europe, the Middle East, and North Africa, licensing its proprietary advancements in diverse medical fields.
What Is the Investment Thesis for VICA?
Rafina Innovations Inc. operates with a dual-division model, combining specialized rehabilitation clinics with a technology development arm, which serves as a key value driver. The Clinic division provides direct patient engagement and potential revenue streams from prosthetics, orthotics, and diabetic foot care services across Southern Europe, the Middle East, and North Africa. The Technology division, focused on developing and licensing proprietary medical devices across diverse fields like bioengineering and robotic surgery, offers significant long-term growth potential through intellectual property commercialization. Growth catalysts include the successful market introduction of new medical devices, expansion of its clinic network into underserved regions, and securing strategic licensing agreements with larger industry players. The increasing global prevalence of chronic diseases, such as diabetes, underpins a growing demand for the company's specialized care and technological solutions. However, investors must consider the company's current financial profile, characterized by negative profit and gross margins (-26.9% and -5.2% respectively), indicating unprofitability and cost challenges. Its market capitalization of $0.00B suggests a micro-cap status, and a high Beta of 9.70 points to extreme stock price volatility. Furthermore, its 'OTC Other' tier listing presents challenges related to liquidity and regulatory oversight, with an unknown disclosure status.
Based on FMP financials and quantitative analysis
VICA Key Highlights
Rafina Innovations Inc. reports a negative Profit Margin of -26.9%, reflecting current unprofitability in its operations.
- The company's Gross Margin stands at -5.2%, indicating that its cost of goods sold currently exceeds its revenue from sales.
- With a Beta of 9.70, VICA exhibits extremely high volatility relative to the broader market, suggesting significant price swings.
- The company operates with a very lean team of 4 employees, indicating a highly focused or early-stage operational structure.
- Rafina Innovations Inc. has a market capitalization of $0.00B, classifying it as a micro-cap entity with limited market valuation.
Who Are VICA's Competitors?
VICA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VICA's Key Strengths?
Dual-division model combining direct patient care clinics with medical technology R&D and licensing.
- Broad scope of R&D across diverse medical fields, including high-growth areas like robotic surgery and bioengineering.
- Proprietary technological advancements and potential for intellectual property licensing.
- Established rehabilitation clinics serving specific regions in Southern Europe, Middle East, and North Africa.
What Are VICA's Weaknesses?
Very small employee base of 4, potentially limiting operational scale and R&D capacity.
- Negative profit margin (-26.9%) and gross margin (-5.2%), indicating current unprofitability and cost challenges.
- Extremely high stock volatility with a Beta of 9.70.
- Trading on the OTC Other tier, which typically entails challenges related to liquidity and regulatory oversight.
What Could Drive VICA Stock Higher?
VICA catalyst: Research and development efforts in advanced medical devices, including prosthetics, orthotics, bioengineering, and robotic surgery, are continuously progressing.
- Successful commercialization and market launch of a new proprietary medical device, potentially generating new revenue streams and validating R&D investments.
- Strategic expansion of the specialized rehabilitation clinic network into new, underserved regions, increasing patient reach and service revenue.
- Securing significant new licensing agreements for its proprietary technological advancements with larger medical technology or pharmaceutical partners.
- Any improvements in financial performance, such as a reduction in negative gross or profit margins, indicating increased operational efficiency or revenue growth.
What Are the Key Risks for VICA?
Financial-distress signal — its Altman Z-Score of -7.26 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-55.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- The company currently reports negative profit and gross margins (-26.9% and -5.2% respectively), indicating sustained unprofitability and operational cost challenges.
- Extremely high stock volatility, evidenced by a Beta of 9.70, exposes investors to significant and unpredictable price fluctuations.
- Operating on the 'OTC Other' tier presents inherent risks including low liquidity, potential for wide bid-ask spreads, and limited regulatory oversight and disclosure.
- Intense competition within the highly innovative and fragmented medical devices industry could hinder market penetration and profitability for new products.
- Delays or failures in obtaining necessary regulatory approvals for new medical devices could significantly impede commercialization efforts and time-to-market.
What Are the Growth Opportunities for VICA?
- Expansion of Clinic Network: Rafina Innovations Inc. has a significant opportunity to expand its specialized rehabilitation clinics beyond its current footprint in Southern Europe, the Middle East, and North Africa. By identifying new regions with unmet needs for advanced prosthetics, orthotics, and diabetic foot care, the company can tap into growing healthcare markets. The global rehabilitation services market is substantial, driven by increasing chronic conditions and an aging population. Strategic expansion, potentially through partnerships or acquisitions, could significantly increase patient reach and revenue streams, leveraging its established operational model and specialized expertise over the next 3-5 years.
- Commercialization of Proprietary Medical Devices: The Technology division's active engagement in creating and developing new medical devices presents a robust growth pathway. Focusing on bringing specific, high-impact devices to market in areas like advanced prosthetics, orthotics, or diabetic foot care solutions could unlock substantial revenue. The global medical device market, particularly for innovative solutions addressing specific conditions, offers considerable potential. Successful commercialization, backed by clinical validation and effective marketing, could establish Rafina as a key innovator and generate significant sales within a 2-4 year timeframe, capitalizing on its R&D investments.
- Strategic Licensing Agreements: Rafina's proprietary technological advancements across diverse fields, including bioengineering, ultrasonics, and robotic surgery, represent valuable intellectual property. Pursuing strategic licensing agreements with larger, established medical device manufacturers or pharmaceutical companies could provide a non-dilutive revenue stream and accelerate market penetration. These partnerships would allow Rafina's innovations to reach a broader global audience without incurring extensive manufacturing and distribution costs. Such agreements, potentially structured as royalty-based deals, could provide stable, long-term revenue growth and validate its technological prowess within the next 1-3 years.
- Advancements in Robotic Surgery and Bioengineering: The company's engagement in robotic surgery and bioengineering positions it in high-growth, cutting-edge segments of the medical technology market. The global robotic surgery market is projected to expand significantly, driven by demand for minimally invasive procedures and improved patient outcomes. By focusing R&D efforts and securing patents in these advanced areas, Rafina can develop high-value intellectual property and specialized devices. Successful innovation and commercialization in these fields could lead to substantial market share and premium pricing, offering a long-term growth trajectory over 5-10 years as these technologies mature and gain wider adoption.
- Addressing the Diabetic Foot Care Market: With the increasing global prevalence of diabetes, the demand for comprehensive diabetic foot care solutions, including preventative, diagnostic, and treatment devices, is experiencing significant growth. Rafina's existing focus on diabetic foot care within its clinics and its technology development arm provides a strong foundation to capitalize on this expanding market. Developing and commercializing innovative products specifically designed for diabetic foot monitoring, wound care, or specialized footwear could tap into a large and consistently growing patient population, offering a sustained growth opportunity over the next 3-7 years.
What Threats Does VICA Face?
- Intense competition from established medical device manufacturers and other innovative startups.
- Significant regulatory hurdles and lengthy approval processes for new medical technologies.
- Challenges in securing adequate funding for ongoing research, development, and commercialization efforts.
- Market acceptance risks for new and innovative medical devices and methodologies.
What Are VICA's Competitive Advantages?
- Proprietary technological advancements and intellectual property across diverse medical fields, including bioengineering and robotic surgery.
- Integrated business model combining direct patient care through clinics with medical technology development, allowing for direct feedback and validation.
- Specialized expertise in niche medical areas such as tissue mechanics, ultrasonics, and advanced diabetic foot care.
- Geographic focus on Southern Europe, the Middle East, and North Africa for clinic operations, potentially establishing regional market presence.
What Does VICA Do?
Founded in 2007, Rafina Innovations Inc., initially known as HCi Viocare until its name change in July 2018, is a medical technology company headquartered in Glasgow, United Kingdom. The company's operations are strategically bifurcated into two distinct yet complementary divisions: its Clinic division and its Technology division. The Clinic division is dedicated to managing specialized rehabilitation clinics, providing essential services in prosthetics, orthotics, and comprehensive diabetic foot care. These clinics serve a broad patient base across Southern Europe, the Middle East, and North Africa, addressing critical needs in these regions for advanced rehabilitative care. This operational arm not only generates revenue but also provides a practical environment for understanding patient needs and potentially testing new technologies developed by the company. Simultaneously, the Technology division forms the core of Rafina Innovations Inc.'s innovation engine. This division is actively engaged in the creation, rigorous development, and strategic market introduction of cutting-edge medical devices, innovative methodologies, and advanced products. The scope of its research and development is extensive, encompassing a wide array of medical fields. These include, but are not limited to, prosthetics, orthotics, general rehabilitation, bioengineering, mobility solutions, advanced diabetes and diabetic foot care technologies, tissue mechanics, ultrasonics, sophisticated medical signal processing and analysis, general medical technology, orthopedics, and the rapidly evolving field of robotic surgery. Furthermore, a key aspect of the Technology division's strategy involves the licensing of its proprietary technological advancements, allowing for broader market penetration and revenue generation through intellectual property. With a lean team of four employees, Rafina Innovations Inc. positions itself as an agile innovator within the specialized segments of the medical technology and rehabilitation sectors.
What Products and Services Does VICA Offer?
- Develop and research advanced medical technologies and innovative methods.
- Commercialize and market proprietary medical devices and products.
- Manage specialized rehabilitation clinics for prosthetics in Southern Europe, Middle East, and North Africa.
- Operate specialized rehabilitation clinics for orthotics in Southern Europe, Middle East, and North Africa.
- Provide comprehensive diabetic foot care services through its network of rehabilitation clinics.
- Engage in bioengineering, tissue mechanics, ultrasonics, and medical signal processing research.
- Develop technologies for general rehabilitation, mobility, orthopedics, and robotic surgery.
- License its proprietary technological advancements to other entities.
How Does VICA Make Money?
- Generates revenue from the operation of specialized rehabilitation clinics offering prosthetics, orthotics, and diabetic foot care services.
- Derives income from the commercialization and direct sales of its proprietary medical devices and innovative products.
- Secures revenue through licensing agreements, allowing other companies to utilize Rafina's patented technological advancements.
- Invests in research and development to create new medical technologies, which are then commercialized or licensed.
What Industry Does VICA Operate In?
Rafina Innovations Inc. operates within the dynamic Healthcare sector, specifically targeting the Medical Devices industry. This industry is characterized by continuous innovation, stringent regulatory requirements, and a growing global demand driven by an aging population and increasing prevalence of chronic diseases. Rafina's strategic focus on specialized rehabilitation, including prosthetics, orthotics, and comprehensive diabetic foot care, positions it within a niche yet expanding segment. The global market for medical devices is projected to grow steadily, fueled by technological advancements in areas such as bioengineering, robotics, and personalized medicine. Rafina's dual approach, combining direct clinic operations with medical technology development and licensing, allows it to address both service delivery and product innovation. The competitive landscape is fragmented, featuring large multinational corporations alongside numerous specialized smaller firms. Rafina aims to differentiate itself through proprietary technological advancements and targeted regional clinic operations, particularly in Southern Europe, the Middle East, and North Africa, where specific healthcare needs may present unique opportunities.
Who Are VICA's Key Customers?
- Patients requiring specialized rehabilitation services for prosthetics and orthotics.
- Individuals seeking comprehensive diabetic foot care solutions and related medical support.
- Healthcare providers, hospitals, and clinics interested in utilizing or integrating Rafina's medical devices.
- Other medical technology companies or pharmaceutical firms looking to license advanced proprietary technologies.
Key Financial Metrics
Return on equity for Rafina Innovations Inc. stands at -55.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -11.4%, showing how much profit it generates from its asset base. A current ratio of 1.18 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
Rafina Innovations Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Glasgow, GB. The company is led by CEO Nikolaos Kardaras. VICA has traded publicly since 2013.
Financial Health
Rafina Innovations Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.26 places it in the distress zone, a signal of elevated financial risk.
Insider Activity
The most recent 12 insider filings for Rafina Innovations Inc. break down as 0 sales and 12 purchases. On net that is roughly 258K shares acquired (about $23K) — insiders putting money in tends to read as conviction.
VICA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Rafina Innovations seems to be gaining traction in the social trading circles, suggesting increased visibility and potential for new investors.
- Recent insider buying activity could signal confidence within the company about future prospects, which is often a good sign.
- The community's overall sentiment appears to be leaning slightly bullish, possibly driven by positive news or developments within the company.
- Market perception indicates Rafina Innovations is being viewed as an innovator, which could attract investors looking for growth potential.
Bear Case
- Some community members are expressing concerns about the company's long-term sustainability in a competitive market.
- There's a perception that Rafina Innovations might be overhyped, leading to potential corrections if expectations aren't met.
- Recent market developments suggest increased volatility in the sector, which could negatively impact Rafina Innovations' stock performance.
- A segment of the community believes the company's current valuation is too high relative to its current performance, suggesting a potential downside risk.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VICA Latest News
No recent news available for VICA.
VICA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VICA.
Price Targets
Wall Street price target analysis for VICA.
VICA MoonshotScore
What does this score mean?
The MoonshotScore rates VICA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Nikolaos Kardaras
Chief Executive Officer
Unknown
Track Record: Unknown
VICA OTC Market Information
Rafina Innovations Inc. trades on the 'OTC Other' tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to strict listing standards regarding financial health, corporate governance, and disclosure, companies on the 'OTC Other' tier have minimal reporting requirements. This tier is typically for companies that do not meet the standards for OTCQX or OTCQB, or choose not to provide financial information. This classification often indicates limited public information and higher inherent risks compared to higher-tiered OTC or exchange-listed securities.
- OTC Tier: OTC Other
- Limited Public Information: The 'OTC Other' tier implies minimal disclosure requirements, leading to a lack of comprehensive and timely financial and operational data for investors.
- Low Liquidity and High Volatility: Shares may be difficult to buy or sell, and prices can be highly volatile due to thin trading volumes and wide bid-ask spreads.
- Lack of Regulatory Oversight: Companies on this tier are subject to less stringent regulatory scrutiny compared to exchange-listed or higher-tier OTC companies, increasing investment risk.
- Potential for Penny Stock Fraud: The 'OTC Other' tier can be susceptible to manipulative practices, including 'pump-and-dump' schemes, due to limited oversight.
- Difficulty in Valuation: The absence of robust financial reporting and analyst coverage makes it challenging to accurately assess the company's intrinsic value.
- Verify any available financial statements, even if unaudited, for consistency and red flags.
- Research management's background, including any past regulatory issues or business failures.
- Scrutinize the company's business model and revenue generation, seeking specific details beyond general descriptions.
- Assess the current trading volume and bid-ask spread to understand potential liquidity challenges.
- Look for any news, press releases, or corporate actions that might provide insights into operations or financial health.
- Investigate any legal or regulatory actions against the company or its executives.
- Consider the company's ability to raise capital and its burn rate, given its negative margins.
- The company has a stated physical headquarters in Glasgow, UK, and a founding year (2007).
- It operates distinct business divisions (Clinic and Technology) with defined services and product development areas.
- The company explicitly mentions licensing proprietary technological advancements, indicating a focus on intellectual property.
- It serves specific geographic regions (Southern Europe, Middle East, North Africa) with its clinic operations.
- The company has a named CEO, Nikolaos Kardaras, despite limited background information.
What Investors Ask About Rafina Innovations Inc. (VICA) — Healthcare
What does Rafina Innovations Inc. do?
Rafina Innovations Inc. is a UK-based medical technology company with a dual operational focus. Its Clinic division manages specialized rehabilitation clinics across Southern Europe, the Middle East, and North Africa, offering critical services in prosthetics, orthotics, and comprehensive diabetic foot care. Concurrently, its Technology division is dedicated to the research, development, and market introduction of innovative medical devices and methodologies.
How does Rafina Innovations Inc. navigate regulatory approval processes for its medical devices?
Rafina Innovations Inc., operating in the medical device sector, must navigate complex and stringent regulatory approval processes to bring its innovations to market. While specific details on their regulatory track record or pending approvals are not provided, successful commercialization of medical devices typically requires adherence to standards set by bodies like the European Medicines Agency (EMA) in Europe or the Food and Drug Administration (FDA) in the United States, depending on target markets.
What are the primary financial challenges facing Rafina Innovations Inc. given its current metrics?
Rafina Innovations Inc. faces several significant financial challenges as indicated by its current metrics. The company reports a negative Profit Margin of -26.9% and a negative Gross Margin of -5.2%, which are strong indicators of unprofitability.
How does Rafina Innovations Inc.'s dual-division model (Clinics and Technology) contribute to its strategy?
Rafina Innovations Inc.'s dual-division model is a strategic approach designed to create synergistic value. The Clinic division, managing specialized rehabilitation centers, provides direct patient interaction and a consistent revenue stream from services like prosthetics, orthotics, and diabetic foot care.
What are the key factors to evaluate for VICA?
Evaluate VICA on fundamentals, analyst consensus, and risk factors. Rafina Innovations Inc. operates with a dual-division model, combining specialized rehabilitation clinics with a technology development arm, which serves as a key value driver. Not financial advice.
How frequently does VICA data refresh on this page?
VICA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VICA's recent stock price performance?
Rafina Innovations Inc. (VICA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Dual-division model combining direct patient care clinics with medical technology R&D and licensing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VICA overvalued or undervalued right now?
Rafina Innovations Inc. (VICA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information regarding the CEO's background, track record, and tenure is not available in the provided source data.
- Specific details on product lines, market share, and competitive advantages beyond general descriptions are limited.
- No FMP PEER TICKERS were provided, therefore the 'competitors' array is empty.
- The disclosure status for the OTC listing is explicitly stated as 'Unknown', limiting transparency.